biospace.com

BMS faces high stakes from milvexian atrial fibrillation trial

Bristol-Myers Squibb logoBristol-Myers Squibb
Sig1.90Sen-5.50Env0.00Soc0.00Gov0.00

Bristol-Myers Squibb is counting on LIBREXIA AF, a Phase 3 milvexian trial in atrial fibrillation, as a key readout for its future outlook. Analysts estimate about 60% odds of success, warning a failure could drop the stock by roughly 40–50%. BMS also expects LIBREXIA AF data next year, while Eliquis faces generics-driven revenue erosion and Opdivo Qvantig is meant to blunt biosimilar impact.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro